News | Breast Imaging | October 01, 2015

Hologic Displays Latest Women’s Health Technologies at RSNA 2015

hologic mammography Selin

October 1, 2015 — The recent KLAS Research women’s imaging report, Women's Imaging 2015. Are New Technologies Delivering Promised Benefits?, notes that Hologic is the undisputed industry leader in mammography and the vendor said it hopes to hold that position. At RSNA 2015, Hologic is featuring a growing family products. At RSNA 2015, the vendor said they expect huge interest to continue in breast tomosynthesis (3-D breastr imaging) offerings. Sixty-five percent of the U.S. mammography providers surveyed by KLAS planned to invest in breast tomosynthesis technology during the next two years, up from 57 percent in 2014 (for more data).

Tomosynthesis continues as a hot topic in the radiology world. Last year, breast tomosynthesis continued its remarkable run by winning the award for Hottest Clinical Procedure by AuntMinnie readers and editors for the fifth straight year. The sustained interest in the technology is being driven by a steady stream of research papers on the technology's positive clinical impact, particularly on breast screening. There are over 60 papers, poster sessions and lectures on breast tomosynthesis listed in the RSNA program this year. 

In the past year, Hologic launched a number of new products to build on our breast tomosynthesis franchise. Five examples include:

Genius 3D Mammography Exams
A Genius 3D Mammography exam is available only on our Selenia Dimensions system. The Genius 3D Mammography exams are proven clinically superior to conventional mammography. Genius exams are helping find breast cancers earlier, while reducing recall rates and false positives. More than 8 million women in the United States have benefited from this breakthrough exam. Genius exams deliver advantages, not only for the women who benefit from early detection, but also for the physicians who care for them and the facilities that offer this lifesaving technology.

C-View Generated 2-D Images From Selenia Dimensions Tomosynthesis Data Sets
The C-View software is designed to generate 2-D images from Genius 3D Mammography image slices, eliminating the need for a separate 2-D exam. The technology benefits, including a reduction in X-ray exposures leading to shorter exam times (less than four second scan per view), and increased patient comfort from the shorter compression time. Published studies including a number of new papers accepted for presentation at RSNA have shown that the use of C-View software results in a clinically superior exam at virtually the same low radiation dose as a conventional 2-D screening exam.

Affirm Tomosynthesis Guided Breast Biopsy
The Affirm 3D-guided breast biopsy product saw huge interest in 2015. This first-of-its-kind technology is designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions not detected in 2-D imaging, or when using other modalities. To date, Hologic is the only company with a tomosynthesis guided breast biopsy option. Affirm is designed to provide numerous advantages over traditional stereotactic biopsy procedures, including faster lesion targeting and reduced patient procedure time. 

I-View Contrast Enhanced 2-D Mammography and Tomosynthesis Fusion
Using an iodinated contrast agent, the I-View software on the Hologic Selenia Dimensions system enables users to image the functional 2-D contrast uptake and the morphological Genius 3D Mammography image in rapid sequence and combine these two image sets into a single fused study. In the fused study, the 2-D contrast image can identify potential lesions based on their physiological state due to an increase in the contrast agent uptake. The Genius 3D Mammography image can then be overlaid on the 2-D contrast image and provide morphological information on the lesion, such as improved visibility of associated spiculations.

I-View dual modality contrast enhanced imaging is designed to confirm findings and localize lesions when breast cancer imaging results are inconclusive. A contrast enhanced exam using I-View software can be performed in less than 10 minutes, in the same exam room, and on thesame popular screening equipment. 

The I-View imaging mode is designed to offer several advantages over conventional contrast breast MRI:

•    Reduced cost.
•    Contrast imaging availability to patients for whom MRI is contraindicated.
•    Access to patients in areas where MRI systems are not available.

I-View  imaging software is an extension of the existing indication for diagnostic imaging with the Hologic Selenia Dimensions system. The product is 510(k) cleared and CE marked.

Quantra Breast Density Assessment For Breast Tomosynthesis 
Quantra v2.1 software is FDA-cleared and compatible for breast tomosynthesis. It features the latest advances in density assessment algorithms, a newly designed, and easy to read Secondary Capture display using BI-RADS fifth edition terminology and user-friendly naming for all Quantra assessed values.

Hologic is also showing other products – from biopsy devices and targeted radiation therapy, to Fluoroscan mini C-arms and new uses for our Horizon bone densitometry systems. Three examples of other products being showing from the interventional solutions business at RSNA include:

Sertera Spring Loaded Biopsy Device 
The newest member of Hologic’s ultrasound-guided breast biopsy family, is a disposable, core needle biopsy device available in multiple gauge sizes. The device is lightweight and designed to be completely armed and fired with one hand for core needle biopsies.

Brevera Breast Biopsy System With CorLumina Imaging Technology
An advanced biopsy platform designed to increase clinical confidence, reduce procedure times and improve the patient experience. 

New Prone Biopsy System
Our new prone biopsy system is a fully redesigned dedicated prone biopsy solution. The prone table uses the latest mammography imaging technology including 3-D imaging. It is designed to make it fast and easy to identify and confidently target lesions, especially those found only using the Genius 3D Mammography exam.

For more information: www.hologic.com

 

Related Content

Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Overlay Init